S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
NEW YORK - TG Therapeutics, Inc. (NASDAQ:TGTX) reported first quarter 2025 results that exceeded revenue expectations but fell short on earnings on Monday.
The company’s shares edged up 0.02% in premarket trading following the announcement.
The biopharmaceutical company posted revenue of $119.7 million for the quarter, surpassing the analyst consensus estimate of $117.13 million. This represents a significant increase from the same quarter last year, though the exact YoY percentage was not provided in the available information.
However, TG Therapeutics reported earnings per share (EPS) of $0.03, missing the analyst estimate of $0.16 by $0.13. The company did not provide an explanation for the earnings shortfall in the given context.
Looking ahead, TG Therapeutics provided an optimistic outlook for the full year 2025. The company expects revenue to reach $575 million, which is above the current analyst consensus of $553 million.
TG Therapeutics focuses on developing and commercializing novel treatments for B-cell diseases. The company’s ability to surpass revenue expectations and provide guidance above consensus estimates indicates potential market traction for its products, despite the earnings miss in the first quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.